{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:37:02Z","timestamp":1761547022929,"version":"build-2065373602"},"reference-count":68,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["508240"],"award-info":[{"award-number":["508240"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thoracic.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Surgery Clinics"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.thorsurg.2018.12.002","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T01:36:43Z","timestamp":1551922603000},"page":"133-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Neurologist\u2019s Perspective on Understanding Myasthenia Gravis"],"prefix":"10.1016","volume":"29","author":[{"given":"Loulwah","family":"Mukharesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry J.","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2013","series-title":"Neuromuscular disorders in clinical practice","key":"10.1016\/j.thorsurg.2018.12.002_bib1"},{"year":"2002","series-title":"Myasthenia gravis. An illustrated history","author":"Keesey","key":"10.1016\/j.thorsurg.2018.12.002_bib2"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S0140-6736(00)94294-6","article-title":"Treatment of myasthenia gravis with physostigmine","volume":"1(5779)","author":"Walker","year":"1934","journal-title":"Lancet"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib4","first-page":"759","article-title":"Case showing the effect of prostigmin on myasthenia gravis","volume":"28","author":"Walker","year":"1935","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/003693306000501001","article-title":"Myasthenia gravis, a new hypothesis","volume":"5","author":"Simpson","year":"1960","journal-title":"Scot Med J"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ncl.2016.08.008","article-title":"Update on ocular myasthenia gravis","volume":"35","author":"Smith","year":"2017","journal-title":"Neurol Clin"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib7","first-page":"826","article-title":"Myasthenia gravis: a clinical-immunological update","volume":"263","author":"Binks","year":"2016","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A\u00a0systemic review of population based epidemiological studies in myasthenia gravis","volume":"18","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/ene.13535","article-title":"A\u00a0nationwide epidemiological study of myasthenia gravis in Latvia","volume":"25","author":"Zieda","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib10","first-page":"707","article-title":"Juvenile myasthenia gravis in Norway: clinical characteristics, treatment, and long-term outcome in a nation-wide population-based cohort","volume":"21","author":"Popperud","year":"2017"},{"issue":"77","key":"10.1016\/j.thorsurg.2018.12.002_bib11","first-page":"1","article-title":"Clinical characteristics of juvenile myasthenia gravis in Southern China","volume":"9","author":"Huang","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib12","series-title":"Myasthenia gravis and related disorders","first-page":"85","article-title":"Clinical presentation and epidemiology of myasthenia gravis","author":"Kuks","year":"2018"},{"issue":"17","key":"10.1016\/j.thorsurg.2018.12.002_bib13","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.0b013e318217e735","article-title":"Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada","volume":"76","author":"Pakzad","year":"2011","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.thorsurg.2018.12.002_bib14","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/j.1532-5415.2000.tb02635.x","article-title":"Clinical characteristics and prognosis of myasthenia gravis in older people","volume":"48","author":"Evoli","year":"2000","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib17","series-title":"Myasthenia gravis and related disorders","first-page":"47","article-title":"Immunopathogenesis of Myasthenia Gravis","author":"Le Panse","year":"2018"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/1744666X.4.1.43","article-title":"Effect of complement and its regulation on myasthenia gravis pathogenesis","volume":"4","author":"Kusner","year":"2008","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/WCO.0b013e328364d6cd","article-title":"Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation","volume":"26","author":"Le Panse","year":"2013","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib20","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/mus.25973","article-title":"B\u00a0cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib21","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib22","doi-asserted-by":"crossref","first-page":"638968","DOI":"10.1155\/2015\/638968","article-title":"Follicular helper CD4+ T cells in human neuroautoimmune diseases and their animal models","volume":"2015","author":"Fan","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib23","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.4049\/jimmunol.1501339","article-title":"Autoreactive T cells from patients with Myasthenia Gravis are characterized by elevated IL-17, IFN-gamma, and GM-CSF and diminished IL-10 production","volume":"196","author":"Cao","year":"2016","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib24","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1586\/1744666X.2015.1047345","article-title":"The role of T regulatory cells in immunopathogenesis of myasthenia gravis: implications for therapeutics","volume":"11","author":"Alahgholi-Hajibehzad","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jneuroim.2015.03.008","article-title":"Regulatory function of CD4+CD25++ T cells in patients with myasthenia gravis is associated with phenotypic changes and STAT5 signaling: 1,25-Dihydroxyvitamin D3 modulates the suppressor activity","volume":"281","author":"Alahgholi-Hajibehzad","year":"2015","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.neulet.2016.07.049","article-title":"Imbalance of circulating CD4(+)CXCR5(+)FOXP3(+) Tfr-like cells and CD4(+)CXCR5(+)FOXP3(-) Tfh-like cells in myasthenia gravis","volume":"630","author":"Wen","year":"2016","journal-title":"Neurosci Lett"},{"issue":"13","key":"10.1016\/j.thorsurg.2018.12.002_bib27","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1056\/NEJMc1701027","article-title":"Myasthenia gravis","volume":"376","author":"Gilhus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/00207454.2017.1344237","article-title":"Factors affecting outcome in ocular myasthenia gravis","volume":"128","author":"Mazzoli","year":"2018","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib30","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CND.0000000000000165","article-title":"Concurrent paraspinous myopathy and myasthenia gravis","volume":"18","author":"Romano","year":"2017","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib31","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","article-title":"Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals","volume":"72","author":"Alshekhlee","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib32","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/jnnp-2017-315782","article-title":"Pattern of ocular involvement in myasthenia gravis with MuSK antibodies","volume":"88","author":"Evoli","year":"2017","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1017\/cjn.2017.253","article-title":"Autoantibodies to low-density lipoprotein receptor-related double seronegative myasthenia gravis: a systemic review","volume":"45","author":"Bacchi","year":"2018","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib35","series-title":"Electromyography and neuromuscular disorders","first-page":"52","article-title":"Repetitive nerve stimulation","author":"Preston","year":"2013"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1590\/0004-282X20130008","article-title":"Stimulated jitter with concentric needle in 42 myasthenia gravis patients","volume":"71","author":"Kouyoumdjian","year":"2013","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0404.1988.tb06970.x","article-title":"Ocular myasthenia: diagnostic and therapeutic problems","volume":"77","author":"Evoli","year":"1988","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib38","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/mus.23857","article-title":"Accuracy of the ice test in the diagnosis of myasthenia gravis in patients with ptosis","volume":"48","author":"Fakiri","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib39","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: association of British neurologists\u2019 management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Pract Neurol"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib41","series-title":"Myasthenia gravis and related disorders","first-page":"169","article-title":"Treatment of myasthenia gravis","author":"Kaminski","year":"2018"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol Clin"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib43","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/11593300-000000000-00000","article-title":"Treatment of myasthenia gravis: focus on pyridostigmine","volume":"31","author":"Maggi","year":"2011","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1600-0404.2006.00733.x","article-title":"The effectiveness of thymectomy on seronegative generalized myasthenia gravis: comparing with seropositive cases","volume":"115","author":"Yuan","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib45","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1600-0404.1991.tb04899.x","article-title":"Effectiveness of steroid treatment in myasthenia gravis: a retrospective study","volume":"84","author":"Cosi","year":"1991","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2017.00230","article-title":"The role of osteopontin and its gene on glucorticoid response in myasthenia gravis","volume":"8","author":"Xie","year":"2017","journal-title":"Front Neurol"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib48","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A\u00a0randomized double blind trial of prednisolone alone or with azathioprine in myasthenia gravis","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib49","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/ene.12108","article-title":"Use of azathioprine for nonthymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark","volume":"20","author":"Pedersen","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib50","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jneuroim.2012.04.016","article-title":"Opportunistic infections in myasthenia gravis treated with mycophenolate mofetil","volume":"249","author":"Termsarasab","year":"2012","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib51","first-page":"42","article-title":"Update on the teratogenicity of maternal mycophenolate mofetil","volume":"4","author":"Coscia","year":"2015","journal-title":"J\u00a0Pediatr Genet"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib52","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1212\/01.wnl.0000173031.56429.04","article-title":"Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil","volume":"65","author":"Vernino","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib53","first-page":"539","article-title":"Retrospective analysis of the use of cyclosporine in myasthenia gravis","volume":"681","author":"Ciafaloni","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib54","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/1756285615571873","article-title":"The emerging role of tacrolimus in myasthenia gravis","volume":"8","author":"Cruz","year":"2015","journal-title":"Therap Adv Neurol Dis"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib55","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10072-016-2769-5","article-title":"Long-term efficacy and side effects of low-dose tacrolimus for the treatment of myasthenia gravis","volume":"38","author":"Tao","year":"2017","journal-title":"Neurol Sci"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib56","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"A\u00a0single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib57","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib58","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/mus.24259","article-title":"Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation","volume":"50","author":"Elenbroker","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib59","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.mbc.0000172694.85233.a8","article-title":"Venous and arterial thrombosis following administration of intravenous immunoglobulins","volume":"16","author":"Paran","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib60","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/mus.23508","article-title":"A\u00a0retrospective study of complications of therapeutic plasma exchange in myasthenia","volume":"47","author":"Guptill","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib61","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/s100720200011","article-title":"High-dose intravenous immunoglobulin G treatment of myasthenia gravis","volume":"1","author":"Ferrero","year":"2002","journal-title":"Neurol Sci"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib62","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib63","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1191\/0961203305lu2138oa","article-title":"Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases","volume":"14","author":"Chambers","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib64","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib65","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib66","series-title":"Myasthenia gravis and related disorders","first-page":"199","article-title":"Thymectomy for non-thymomatous myasthenia gravis","author":"Sonett","year":"2018"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib67","series-title":"Myasthenia gravis and related disorders","first-page":"275","article-title":"Toxic neuromuscular transmission disorders","author":"Howard","year":"2018"},{"key":"10.1016\/j.thorsurg.2018.12.002_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.0000000000006278","article-title":"Pearls and oysters: case report: pembrolizumab induced myasthenia gravis","volume":"91","author":"Algaeed","year":"2018","journal-title":"Neurology"}],"container-title":["Thoracic Surgery Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547412718301580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547412718301580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:32:25Z","timestamp":1761546745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547412718301580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1547412718301580"],"URL":"https:\/\/doi.org\/10.1016\/j.thorsurg.2018.12.002","relation":{},"ISSN":["1547-4127"],"issn-type":[{"type":"print","value":"1547-4127"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Neurologist\u2019s Perspective on Understanding Myasthenia Gravis","name":"articletitle","label":"Article Title"},{"value":"Thoracic Surgery Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thorsurg.2018.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}